Senate approves bill expanding calcium scanning and access to cholesterol medicines, sponsor cites large savings

Senators passed the tax/business/transportation committee substitute for Senate Bill 443 after floor debate over screening for coronary artery disease and insurance coverage for cholesterol-lowering medication.

Sponsor Senator Hickey told the Senate the bill centers on detecting coronary artery disease with calcium scanning and expanding access to medication that lowers low-density lipoprotein (LDL). He said the clinical aim is to reduce LDL toward a level “about 50 milligrams per deciliter,” and described generational, low-cost statin therapy he said costs about “50 to 60¢ a day.” Hickey said lowering LDL and treating detected disease could save roughly "$4,000,000,000" in state health-care expenses and “about 2,000 lives,” as stated on the floor.

Supporters framed the bill as a public-health and long-term fiscal measure. Senator Hickey said the science shows immediate benefit after disease confirmation, and he referenced preventive care access expectations under U.S. Preventive Services Task Force guidance when discussing co-pay elimination. Opponents, including Senator Townsend and Senator Scott, questioned whether eliminating a co-pay would shift near-term costs onto insurers and carriers, and whether the state had the data to show an immediate reduction in insurer exposure or in short-term harms during any cost-shift period. Senator Scott criticized extrapolations that treating disease through co-pay elimination would “eliminate coronary heart disease.”

Senator Hickey moved final passage on the floor; the clerk recorded a roster of senators who voted in the negative by raised hands (named on the floor as: Senator Yazzell, Senator DeBison, Senator Sherr, Senator Brantley, Senator Thornton, Senator Paul, Senator Townsend, Senator Woods, Senator Scott, Senator Gallegos, Senator Brent). The presiding officer announced the substitute “has duly passed the Senate.”

The debate focused on: (1) public-health effects of earlier detection using calcium scans; (2) the clinical goal of lowering LDL and the role of statins; and (3) near-term fiscal effects on insurers and premium formation if co-pays are reduced or eliminated.

Senator Hickey’s floor presentation and the named votes are part of the official record; the bill now proceeds under the legislative process for transmission to the next step.

Details recorded on the floor included the sponsor’s cost and outcome estimates (LDL target ~50 mg/dL; estimated medication cost ~50–60¢ per day; cited $4 billion in state savings; cited ~2,000 lives saved). The sponsor described screening as recommended at age 50.

This article is based on senators’ on-the-record floor remarks and the floor vote roll call excerpts during consideration of Senate Bill 443.

Ending — The bill passed the Senate on final passage; the transcript shows named senators voting no as recorded on the floor. Additional fiscal and actuarial details (for example, insurer premium modeling) were discussed on the floor but not produced as supporting documents during the debate and would require follow-up with the Department of Insurance or fiscal analysts for independent verification.